Medicure Inc (MPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicure Inc (MPH) has a cash flow conversion efficiency ratio of -0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-519.00K ≈ $-375.44K USD) by net assets (CA$17.31 Million ≈ $12.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medicure Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Medicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Medicure Inc for a breakdown of total debt and financial obligations.
Medicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
-0.303x |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
0.006x |
|
Finexia Financial Group Ltd
AU:FNX
|
-0.436x |
|
Tempo Inti Media Tbk
JK:TMPO
|
-0.034x |
|
Azevedo & Travassos S.A
SA:AZEV3
|
0.479x |
|
Batero Gold Corp
V:BAT
|
-0.003x |
|
Bon Natural Life Ltd
NASDAQ:BON
|
0.076x |
|
YKGI Holdings Bhd
KLSE:7020
|
0.164x |
Annual Cash Flow Conversion Efficiency for Medicure Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Medicure Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Medicure Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$20.78 Million ≈ $15.03 Million |
CA$1.38 Million ≈ $996.10K |
0.066x | -36.58% |
| 2023-12-31 | CA$19.90 Million ≈ $14.39 Million |
CA$2.08 Million ≈ $1.50 Million |
0.104x | +20.07% |
| 2022-12-31 | CA$21.00 Million ≈ $15.19 Million |
CA$1.83 Million ≈ $1.32 Million |
0.087x | -59.83% |
| 2021-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$3.99 Million ≈ $2.89 Million |
0.217x | +285.19% |
| 2020-12-31 | CA$19.15 Million ≈ $13.85 Million |
CA$-2.24 Million ≈ $-1.62 Million |
-0.117x | +78.47% |
| 2019-12-31 | CA$26.94 Million ≈ $19.49 Million |
CA$-14.64 Million ≈ $-10.59 Million |
-0.543x | -6219.98% |
| 2018-12-31 | CA$83.59 Million ≈ $60.47 Million |
CA$742.27K ≈ $536.95K |
0.009x | -96.73% |
| 2017-12-31 | CA$80.71 Million ≈ $58.38 Million |
CA$21.92 Million ≈ $15.86 Million |
0.272x | +65.07% |
| 2016-12-31 | CA$38.96 Million ≈ $28.18 Million |
CA$6.41 Million ≈ $4.64 Million |
0.165x | +414.14% |
| 2015-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$142.79K ≈ $103.30K |
0.032x | +126.41% |
| 2014-12-31 | CA$-3.91 Million ≈ $-2.83 Million |
CA$473.97K ≈ $342.86K |
-0.121x | -542.33% |
| 2013-12-31 | CA$-5.88 Million ≈ $-4.25 Million |
CA$110.88K ≈ $80.21K |
-0.019x | -108.24% |
| 2012-12-31 | CA$-4.33 Million ≈ $-3.13 Million |
CA$-990.48K ≈ $-716.50K |
0.229x | +199.88% |
| 2011-12-31 | CA$-1.82 Million ≈ $-1.32 Million |
CA$417.29K ≈ $301.86K |
-0.229x | -1190.93% |
| 2010-12-31 | CA$-26.89 Million ≈ $-19.45 Million |
CA$477.48K ≈ $345.40K |
-0.018x | -130.50% |
| 2009-12-31 | CA$-24.96 Million ≈ $-18.05 Million |
CA$-1.45 Million ≈ $-1.05 Million |
0.058x | -89.08% |
| 2008-12-31 | CA$-19.55 Million ≈ $-14.14 Million |
CA$-10.42 Million ≈ $-7.54 Million |
0.533x | -91.65% |
| 2007-12-31 | CA$-6.56 Million ≈ $-4.74 Million |
CA$-41.86 Million ≈ $-30.28 Million |
6.386x | +967.70% |
| 2006-12-31 | CA$34.31 Million ≈ $24.82 Million |
CA$-25.25 Million ≈ $-18.26 Million |
-0.736x | -115.75% |
| 2005-12-31 | CA$37.17 Million ≈ $26.89 Million |
CA$-12.68 Million ≈ $-9.17 Million |
-0.341x | +79.25% |
| 2004-12-31 | CA$7.34 Million ≈ $5.31 Million |
CA$-12.07 Million ≈ $-8.73 Million |
-1.644x | -476.36% |
| 2003-12-31 | CA$21.57 Million ≈ $15.60 Million |
CA$-6.15 Million ≈ $-4.45 Million |
-0.285x | +64.61% |
| 2002-12-31 | CA$4.94 Million ≈ $3.58 Million |
CA$-3.98 Million ≈ $-2.88 Million |
-0.806x | -73.80% |
| 2001-12-31 | CA$8.99 Million ≈ $6.50 Million |
CA$-4.17 Million ≈ $-3.01 Million |
-0.464x | +34.57% |
| 2000-12-31 | CA$3.85 Million ≈ $2.79 Million |
CA$-2.73 Million ≈ $-1.97 Million |
-0.709x | -- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more